US Stock MarketDetailed Quotes
LTRN Lantern Pharma
- 3.280
- -0.030-0.91%
Trading Nov 4 14:24 ET
35.31MMarket Cap-1987P/E (TTM)
3.320High3.140Low19.83KVolume3.190Open3.310Pre Close63.98KTurnover0.25%Turnover RatioLossP/E (Static)10.76MShares11.99052wk High1.14P/B26.06MFloat Cap3.04052wk Low--Dividend TTM7.94MShs Float24.840Historical High--Div YieldTTM5.44%Amplitude2.380Historical Low3.226Avg Price1Lot Size
Lantern Pharma Stock Forum
Sign in to post a comment
$China Pharma (CPHI.US)$ $Bright Minds Biosciences (DRUG.US)$ $Lantern Pharma (LTRN.US)$ $Cytosorbents (CTSO.US)$ $Intensity Therapeutics (INTS.US)$ $Multi Ways (MWG.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $X3 Holdings (XTKG.US)$ $Protagenic Therapeutics (PTIX.US)$ $GRI Bio (GRI.US)$ $Paranovus Entertainment Technology (PAVS.US)$ $VSee Health (VSEE.US)$
📊⚡️📊
📊⚡️📊
2
1
$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE
$Hall Of Fame Resort & Entertainment (HOFV.US)$ $Vera Bradley (VRA.US)$ $Lantern Pharma (LTRN.US)$ $Passage Bio (PASG.US)$ $Sadot (SDOT.US)$ $EDC Publishing (EDUC.US)$ $SHL Telemedicine (SHLT.US)$ $Altamira Therapeutics (CYTO.US)$ $Indaptus Therapeutics (INDP.US)$ $QT Imaging (QTI.US)$ $MediaCo (MDIA.US)$ $Edesa Biotech (EDSA.US)$ $Expion360 (XPON.US)$ $Tevogen Bio Holdings (TVGN.US)$
1
$Lantern Pharma (LTRN.US)$
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
• Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma.
• This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors)....
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
• Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma.
• This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors)....
$Lantern Pharma (LTRN.US)$ This possible play is purely chart driven! Thats the reason im sharing. So those that asked. Here is a example of some of what i look for. This is what brought my attention here🤔🤫
4
1
$Lantern Pharma (LTRN.US)$
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:
1. LP-18...
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:
1. LP-18...
2
Lantern Pharma Announces Positive Clinical Update from Phase 2 HARMONIC™ Clinical Trial.
Lantern Pharma, a company specializing in the use of artificial intelligence (AI) for the development of cancer therapies, has recently shared promising preliminary results from its ongoing Phase 2 HARMONIC™ clinical trial. This study focuses on never smokers with advanced NSCLC, specifically lung adenocarcinoma, who have devel...
Lantern Pharma, a company specializing in the use of artificial intelligence (AI) for the development of cancer therapies, has recently shared promising preliminary results from its ongoing Phase 2 HARMONIC™ clinical trial. This study focuses on never smokers with advanced NSCLC, specifically lung adenocarcinoma, who have devel...
1
$Lantern Pharma (LTRN.US)$
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirm...
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirm...
$Lantern Pharma (LTRN.US)$
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
1
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration $Lantern Pharma (LTRN.US)$
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
jimmy the trader : $China Pharma (CPHI.US)$ broths